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IMPORTANCE Detailed information on the prevalence, associations, and consequences of
anemia and iron deficiency in epidemiologically representative outpatients with chronic heart
failure (HF) is lacking.
OBJECTIVE To investigate the epidemiology of anemia and iron deficiency in a broad range of
patients referred to a cardiology clinic with suspected HF.
DESIGN, SETTING, AND PARTICIPANTS We collected clinical data, including hemoglobin, serum
iron, transferrin saturation, and serum ferritin concentrations, on consecutive patients
referred with suspected HF to a single outpatient clinic serving a local community from
January 1, 2001, through December 31, 2010. Follow-up data were censored on December 13,
2011. Patients underwent phenotyping by echocardiography and plasma N-terminal
pro–brain natriuretic peptide measurement and were followed for up to 10 years.
MAIN OUTCOMEMEASURES Prevalences of anemia and iron deficiency and their
interrelationship, all-cause mortality, and cardiovascular mortality.
RESULTS Of 4456 patients enrolled in the study, themedian (interquartile range) age was 73
(65-79) years, 2696 (60.5%) weremen, and 1791 (40.2%) had left ventricular systolic
dysfunction (LVSD). Of those without LVSD, plasma N-terminal pro–brain natriuretic peptide
concentration was greater than 400 pg/mL in 1172 (26.3%), less than 400 pg/mL in 841
(18.9%), and not measured in 652 (14.6%). Overall, 1237 patients (27.8%) had anemia, with a
higher prevalence (987 [33.3%]) in patients whomet the criteria for HF with or without LVSD.
Depending on the definition applied, iron deficiency was present in 270 (43.2%) to 425
(68.0%) of patients with and 260 (14.7%) to 624 (35.3%) of patients without anemia. Lower
hemoglobin (hazard ratio 0.92; 95% CI, 0.89-0.95; P < .001) and serum iron (hazard ratio
0.98; 95% CI, 0.97-0.99; P = .007) concentrations were independently associated with
higher all-cause and cardiovascular mortality in multivariable analyses.
CONCLUSIONS AND RELEVANCE Anemia is common in patients with HF and often associated
with iron deficiency. Both anemia and iron deficiency are associated with an increase in
all-cause and cardiovascular mortality andmight both be therapeutic targets in this
population.
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A nemia iscommoninpatientswithheart failure (HF)andassociated with more severe symptoms and an ad-verse prognosis1; further investigation often reveals
blood indexes that suggest irondeficiency,whichmay also be
associated with an adverse outcome.1,2 However, not all pa-
tients who appear iron deficient have anemia. The preva-
lence and association of anemia and iron deficiency depend
on how they are defined. Blood hemoglobin and iron indexes
have a continuous distribution. Small changes in values used
to define what is abnormal can have marked effects on the
prevalence of anemia or iron deficiency,making it difficult to
understand the association between these conditions.
Anemia and iron deficiency not only indicate an adverse
prognosis but also are potential targets for therapy in pa-
tients with HF.3-5 If anemia persists despite correction of iron
deficiency, then erythropoiesis-stimulating peptides may be
administered to stimulateerythrocyteproduction.6-9Whether
anemiaor irondeficiency is thekeydriver ofworsening symp-
tomsandprognosis inpatientswithHForwhether each is im-
portant in its own right is currently uncertain. A large trial re-
vealed that darbepoeitin alfa could increase hemoglobin
concentrations, but this resulted only in a modest improve-
ment in quality of life and no reduction in hospitalizations or
death.10 However, two medium-sized randomized clinical
trials4,11 of intravenous ironsuggested improvements in symp-
toms, functional class, and morbidity, which did not appear
to be related to the severity of anemia.
Understanding the interplay of HF, anemia, and iron de-
ficiency is also hampered by the lack of universally accepted
diagnostic criteria for HF. Anemiamight simply be amanifes-
tation of age and comorbidity in this population. Accord-
ingly,we investigated theepidemiologyof anemiaand ironde-
ficiency in a broad range of patients referred to a cardiology
clinic with suspected HF.
Methods
Patients referred with suspected HF to a cardiology outpa-
tient clinic servingamixedurban-rural community (Kingston-
upon-Hull and East Riding of Yorkshire, United Kingdom;
population, approximately 550000) from January 1, 2001,
throughDecember 31, 2010,were invited toparticipate in this
study.Follow-updatawerecensoredonDecember 13,2011.The
only exclusion criterion was the inability to provide valid in-
formed consent because of age younger than 18 years or im-
portant cognitive dysfunction. Patientswith severe renal dis-
easewerenotexcluded,butnopatientundergoingdialysiswas
referred or included. Patients gave written informed consent
for their data to be stored electronically and used for re-
search. Precise records were not kept, but less than 2% of pa-
tients approached are thought to have refused to participate
orwereexcluded.Thestudywasapprovedby theHull andEast
Yorkshire Local Research Ethics Committee.
Patients provided written informed consent. Patient in-
formationwasheldconfidentiallyby theclinical research team
who also cared for them. Personal identifiers were removed
before analysis. Consenting patients received a standardized
symptom questionnaire and underwent clinical examina-
tion,electrocardiography,andechocardiography.Venousblood
samples were taken for standard hematologic and biochemi-
cal testing. Most patients had N-terminal pro–brain natri-
ureticpeptide (NT-proBNP)andhigh-sensitivityC-reactivepro-
tein (hsCRP)measured. Anemiawas defined according to the
WorldHealthOrganization (WHO)criteriaasahemoglobincon-
centration of less than 12.0 g/dL in women and less than 13.0
g/dL inmen(toconvert togramsper liter,multiplyby10).1Ane-
mia was subclassified as mild if the hemoglobin concentra-
tion was less than 1 g/dL, moderate if 1 to 2 g/dL, andmarked
if more than 2 g/dL below the WHO definition. Patients with
hemoglobin concentrations less than 1 g/dL above the WHO
definitionwere considered tohaveborderline anemia.Hema-
tinic factorswere serumironandtransferrin saturation (TSAT),
ferritin, vitamin B12, and red blood cell or serum folate. Be-
cause the clinic was designed to deliver one-stop investiga-
tions, hematinic factorsweremeasuredwithoutknowledgeof
the hemoglobin concentration or clinical diagnosis. The local
laboratory-defined lower limits are less than 45 μg/dL for se-
rumiron (toconvert tomicromolesper liter,multiplyby0.179),
less than 30 ng/mL for ferritin (to convert to picomoles per li-
ter, multiply by 2.247), less than 15% for TSAT, less than 180
pg/mL for vitamin B12 (to convert to picomoles per liter, mul-
tiply by 0.7378), less than 3 ng/mL for serum folate (to con-
vert to nanomoles per liter, multiply by 2.266), and less than
147 ng/mL for red blood cell folate (to convert to nanomoles
per liter,multiply by 2.266). Additional cut points of less than
67 μg/dL for serum iron, less than 100 ng/mL for ferritin, and
less than 20% for TSAT were used to explore different pos-
sible threshold definitions for iron deficiency used in a previ-
ous study.4
There is also a spectrum of cardiac dysfunction and hier-
archy of evidence to support a diagnosis of HF. In 2008, the
EuropeanSociety ofCardiologyguidelines indicated that adi-
agnosis of HF was unlikely if the plasma NT-proBNP concen-
trationwas less than400pg/mL (to convert to nanogramsper
liter,multiply by 1).12 Accordingly, patientswere assigned to 1
of the following 5 cardiac phenotypes based on echocardiog-
raphyandmeasurementofNT-proBNP: (1) left ventricular sys-
tolic dysfunction (LVSD) defined as a left ventricular ejection
fraction less than 40%; (2) left ventricular ejection fraction
Key Points
Questions What is the prevalence, using various definitions, of
anemia and hematinic deficiencies in patients with heart failure
and how are they related to prognosis?
Findings In this observational study of 4456 patients referred to a
community-based heart failure clinic, anemia was present in
one-third of patients, of whom two-thirds had iron deficiency.
Both anemia andmarkers of iron deficiency, except ferritin, were
associated with a poorer prognosis, including an excess of cancer
deaths.
Meaning In patients with heart failure, anemia is commonly
associated with iron deficiency, and anemia and iron deficiency
may both be therapeutic targets.
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greater than 40%but left ventricular diastolic dysfunction or
hypertrophyandplasmaNT-proBNPconcentrationgreater than
400 pg/mL (HFnEF type 1); (3) no substantial echocardio-
graphic abnormalitywith a plasmaNT-proBNP concentration
greater than 400 pg/mL (HFnEF type 2); (4) no substantial
echocardiographicabnormalitywithaplasmaNT-proBNPcon-
centration less than 400 pg/mL (not HF); and (5) no substan-
tial echocardiographic abnormality but no measurement of
NT-proBNP (HF uncertain).
Patientswere followedup clinically andby electronic rec-
ords in primary and secondary care. Follow-upwas censored
at lastcontactordeath.Deathswereadjudicatedbasedonavail-
able records before and surrounding the time of death. Pa-
tients with symptoms of HF at rest or minimal exertion (New
York Heart Association Class IV) or recurrent hospitalization
for HF were generally classified as deaths attributable to HF.
Out-of-hospital deaths that could not be attributed to cancer,
HF, or other end-stage disease were considered sudden.
Continuousvariableswere summarizedusingmedianand
interquartile range (IQR) and compared using Kruskal-Wallis
ranktests; categoricalvariableswereexpressedasnumbersand
percentages and compared using χ2 tests. Univariate analy-
ses were based on data without imputation. Multiple regres-
sionmodels were used to investigate correlation among vari-
ables. Missing values were imputed based on 10 imputations
using a chained equation13,14 similar to the Gibbs sampler.15
Multivariable linear regression was used for continuous vari-
ablesandordinal logistic regressionfororderedcategoricalvari-
ables. Variableswith ahighpercentageofmissing valueswere
not included in multivariable analysis to reduce uncertainty.
Standardized (or β) coefficient was used to measure the
strength of the association of independent to dependent
variables.16,17 Logistic regression models were used to iden-
tify variables associatedwith anemia and irondeficiency, and
Coxproportionalhazards regressionmodelswereused to iden-
tify variables associatedwith all-causeor cardiovascularmor-
tality. Models were not overfitted.18,19 For each cardiac phe-
notype, the associationbetweenpredictedprobabilities of all-
causemortalityat2yearsandpredictorwereconstructedbased
onmultivariable logistic regressionmodelsadjustedforageand
sex and illustrated using probability curves. Venn diagrams
were used to illustrate the associations between anemia and
indexes of iron deficiency. Statistical analyses were per-
formed with STATA statistical software, version 12.1 (Stata-
Corp). The 2-tailed level of statistical significance was set at
P < .05.
Results
Of 4456 patients, the median (IQR) age was 73 (65-79) years,
1760 (39.5%)werewomen, 1791 (40.2%)hadLVSD,707 (15.9%)
hadHFnEF type 1, 465 (10.4%)hadHFnEF type 2, 841 (18.9%)
were considered not to have HF, and 652 (14.6%) had no
major echocardiographic abnormality but did not have
NT-proBNPmeasured. Patients with HFnEF by either defini-
tion were older; those with LVSD were more likely to be men
(Table). The median potential duration of follow-up was 7.7
(IQR, 4.8-9.0) years or, if censored at time of death,which oc-
curred in 1964 patients (44.1%), 4.7 (IQR 2.5-7.6) years; 4261
patients (95.6%) were followed up, dead or alive, for a mini-
mum of 3 years.
Overall, 1237patients (27.8%)hadanemia,whichwasmild
in 643 (14.4%), moderate in 354 (7.9%), and marked in 240
(5.4%) (Figure 1). The prevalence of anemia was higher in
patients with LVSD (597 [33.3%]) or with either definition of
HFnEF (232 [32.8%] and 148 [34.0%] in types 1 and 2, respec-
tively) than in those who lacked echocardiographic and bio-
marker criteria for HF (113 [13.4%]) (Figure 2). An additional
1022 patients (22.9%) had borderline anemia, but the preva-
lence was similar in patients with andwithout HF. There was
astrongassociationbetweentheprevalenceofanemiaandage,
especially in men, but only a weak association with sex
(Figure 3A).
A serum iron concentration was available in 3545 pa-
tients (79.6%) and was less than 45 μg/dL in 497 (14.0%) and
less than67μg/dL in 1296 (36.6%). Patientswith anemiawere
much more likely to have low serum iron concentrations re-
gardless of cardiac phenotype. Less than 5% of patients with
ahemoglobin concentration lower than 1 g/dLabove theWHO
threshold had a serum iron concentration less than 45 μg/dL
compared with greater than 45% of those with a hemoglobin
concentration greater than 1 g/dL below the WHO threshold.
For a given serum iron concentration or TSAT, patients with
HF, regardless of cardiac phenotype, had a higher prevalence
of anemia than patients without HF (Figure 3B and C). Thus,
patientswithHFweremore likely tohavea lowserumironcon-
centration and more likely to have anemia when serum iron
concentrationwas low. Serum ironwashighly correlatedwith
TSAT (r = 0.906; P < .001), mean corpuscular hemoglobin
(r = 0.462;P < .001), andmeancorpuscularvolume (r = 0.273;
P = .001) but only weakly with ferritin (r = 0.207; P = .01).
Serum ferritinwasmeasured in 3373patients (75.7%) and
was less than30ng/mL in478 (10.7%)and less than 100ng/mL
in 1951 (43.8%) (Figure3D).Despite ahigherprevalenceof ane-
mia, patients with LVSD were less likely to have a low serum
ferritin concentration than those without HF. Many patients
hada serumferritin concentration less than 100ng/mLbutdid
not have anemia. The prevalence of anemia was poorly re-
lated to serum ferritin.
Vitamin B12 was measured in 3805 patients (85.4%), red
blood cell folate in 2553 patients (57.3%), and serum folate in
1191 patients (26.7%). Patients with vitamin B12 or folate con-
centrationbelow the laboratory reference rangewereuncom-
mon, and prevalence did not differ by cardiac phenotype
(Figure 3EandF). Theprevalenceof anemia increased slightly
with higher, rather than lower, serum vitamin B12 and folate
concentrations. Patients with HF had a slightly higher preva-
lence of macrocytosis regardless of hemoglobin category
(Figure 2). There was also a strong association between the
prevalenceof anemiaandestimatedglomerular filtration rate,
hsCRP, and NT-proBNP (Figure 3G-I).
Overall, amongst 2395 patients with complete hematinic
data, 1020 patients (42.6%) had anemia or fulfilled 1 or more
of themore conservative criteria for iron deficiency and 1808
(75.5%) if more liberal criteria for iron deficiency were
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Table. Clinical Characteristics and Hematologic Profile by Cardiac Phenotypea
Variable
No. of
Patients
(% Missing)
Overall
(n = 4456)
LVSD
(n = 1791)
HFnEF Type 1
(n = 707)
HFnEF Type 2
(n = 465)
Not HF
(n = 841)
No LVSD but
Missing
NT-proBNP
(n = 652) P Valueb
Age, y 4456 (0) 73 (65-79) 72 (64-78) 77 (69-82) 76 (69-82) 69 (61-76) 72 (65-78) <.001
Men 4456 (0) 2696 (60.5) 1330 (74.3) 315 (44.6) 283 (60.9) 440 (52.3) 328 (50.3) <.001
IHD 4456 (0) 2132 (47.8) 1174 (65.5) 224 (31.7) 220 (47.3) 293 (34.8) 221 (33.9) <.001
COPD 4456 (0) 480 (10.8) 187 (10.4) 64 (9.1) 49 (10.5) 95 (11.3) 85 (13.0) .19
Diabetes 4456 (0) 845 (19.0) 380 (21.2) 117 (16.5) 97 (20.9) 133 (15.8) 118 (18.1) .004
NYHA Class III/IV 4456 (0) 1126 (25.3) 646 (36.1) 176 (24.9) 105 (22.6) 110 (13.1) 89 (13.7) <.001
BMI 4359 (2.2) 28 (25-32) 27 (24-31) 27 (24-31) 28 (26-33) 30 (26-34) 29 (26-33) <.001
Heart rate (ECG), /min 4227 (5.1) 71 (61-84) 74 (63-88) 72 (60-84) 70 (60-82) 69 (60-78) 69 (61-80) <.001
Rhythm (ECG) sinus 4456 (0) 3230 (72) 1206 (67) 410 (58) 257 (55) 803 (95) 554 (85) <.001
Systolic BP, mm Hg 4279 (4.0) 139 (121-157) 128 (112-144) 146 (128-163) 141 (126-160) 147 (130-165) 147 (130-164) <.001
Edema (more than
trivial)
4456 (0) 873 (20) 382 (21) 175 (25) 94 (20) 127 (15) 95 (15) <.001
NT-proBNP, pg/mL 2963 (33.5) 748
(195-2182)
1759
(726-3964)
1252
(638-2575)
959
(629-1811)
122
(60-214)
NA Not done
hsCRP, mg/L 3062 (31.3) 3.90
(1.70-8.10)
4.7
(1.9-9.1)
4.1
(1.6-8.7)
3.7
(1.7-9.9)
3.3
(1.4-6.0)
4.0
(1.6-7.6)
<.001
Sodium, mEq/L 4049 (9.1) 139
(137-141)
139
(136-141)
139
(137-141)
139
(137-141)
139
(138-141)
139
(137-141)
<.001
eGFR (4-variable),
mL/min/1.73 m2
4049 (91) 61.8
(47.8-76.4)
58
(45-72)
59
(46-71)
58
(44-73)
72
(59-84)
66
(50-81)
<.001
Hemoglobin, g/dL 4456 (0) 13.5
(12.3-14.6)
13.5
(12.2-14.5)
13.0
(11.9-14.2)
13.2
(12.1-14.4)
13.8
(12.9-14.8)
13.7
(12.5-14.7)
<.001
Anemia (WHO
definition)
4456 (0) 1237
(28%)
597
(33%)
232
(33%)
158
(34%)
113
(13%)
137
(21%)
<.001
MCHC, pg/cell 4363 (2.1) 29.8
(28.5-31.0)
29.8
(28.3-31.1)
29.6
(28.0-31.0)
29.9
(28.5-31.0)
29.9
(28.8-31.0)
30.0
(28.7-31.1)
.01
MCV, μm3 4432 (0.5) 91.5
(87.9-95.1)
91.6
(87.8-95.6)
91.7
(87.8-95.6)
91.7
(88.0-95.3)
91.0
(87.9-94.1)
91.8
(88.1-94.9)
.11
Iron, μg/dL 3545 (20.4) 84
(61-101)
78
(56-101)
73
(56-101)
78
(84-101)
89
(67-106)
84
(89-106)
<.001
Transferrin saturation,
%
2751 (38.3) 23.0
(17.0-29.0)
22.0
(16.0-30.0)
19.0
(14.0-27.0)
23.0
(17.8-30.0)
24.0
(18.0-29.0)
23.0
(18.0-30.0)
<.001
Ferritin, ng/mL 3373 (24.3) 83
(45-150)
92
(50-169)
68
(39-130)
96
(50-167)
76
(41-139)
79
(42-135)
<.001
Red blood cell folate,
ng/mL
2553 (42.7) 364
(254-523)
372
(260-533)
354
(239-501)
393
(263-558)
350
(248-480)
358
(248-525)
.02
Serum folate, ng/mL 1191 (73.3) 6.5
(4.3-10.1)
6.4
(4.1-10.0)
7.5
(4.8-10.7)
6.5
(4.3-10.7)
6.2
(4.4-10.1)
6.6
(4.4-10.0)
.28
Vitamin B12, pg/mL 3805 (14.6) 325
(243-437)
332
(249-454)
345
(243-467)
334
(252-435)
307
(234-418)
309
(231-416)
<.001
Loop diuretic 4456 (0) 2565 (57.6) 1313 (73.3) 405 (57.3) 299 (64.3) 303 (36.0) 245 (37.6) <.001
Thiazide diuretic 4456 (0) 273 (6.1) 55 (3.1) 45 (6.4) 34 (7.3) 91 (10.8) 48 (7.4) <.001
Loop or thiazide
diuretic
4456 (0) 2766 (62.1) 1335 (74.5) 442 (63.5) 321 (69.0) 382 (45.4) 286 (43.9) <.001
MRA 4456 (0) 639 (143) 456 (25.5) 60 (8.5) 53 (11.4) 32 (3.8) 38 (5.8) <.001
β-Blocker 4456 (0) 1967 (44.1) 952 (53.2) 274 (38.8) 230 (49.5) 282 (33.5) 229 (35.1) <.001
ACE or ARB 4456 (0) 2737 (61.4) 1351 (75.4) 390 (55.2) 285 (61.3) 394 (46.8) 317 (48.6) <.001
Digoxin 4456 (0) 608 (13.6) 292 (16.3) 169 (23.9) 91 (19.6) 18 (2.1) 38 (5.8) <.001
Aspirin 4456 (0) 1948 (43.7) 835 (46.6) 257 (36.4) 203 (43.7) 377 (44.8) 276 (42.3) <.001
Warfarin sodium 4456 (0) 823 (18.5) 419 (23.4) 179 (25.3) 131 (28.2) 26 (3.1) 68 (10.4) <.001
Abbreviations: ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; BMI, bodymass index (calculated as the weight in kilograms
divided by height in meters squared); BP, blood pressure; COPD, chronic
obstructive pulmonary disease; ECG, electrocardiography; eGFR, estimated
glomerular filtration rate; HF, heart failure; HFnEF, HF with preserved left
ventricular ejection fraction (type 1 is defined as echocardiographic
abnormalities that could account for symptoms and NT-proBNP concentration
>400 pg/mL, and type 2 is defined as no LVSD but NT-proBNP concentration
>400 pg/mL); hsCRP, high-sensitivity C-reactive protein; IHD, ischemic heart
disease; IQR, interquartile range; LVSD, left ventricular systolic dysfunction;
MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular
volume; MRA, mineralocorticoid antagonist; NT-proBNP, N-terminal pro–brain
natriuretic peptide; NYHA, New York Heart Association.
SI conversion factors: To convert NT-proBNP to nanograms per liter, multiply by
1; hsCRP to nanomoles per liter, multiply by 9.524; sodium tomillimoles per liter,
multiply by 1; hemoglobin to grams per liter, multiply by 10; MCV to femtoliters,
multiply by 1; iron tomicromoles per litre, multiply by 0.179; ferritin to
picomoles per liter, multiply by 2.247; folate to nanomoles per liter, multiply by
2.266; and vitamin B12 to picomoles per liter, multiply by 0.7378.
a Continuous variables are presented as median (IQR), and categorical variables
are presented as number (percentage).
b The χ2 test or Kruskal-Wallis rank test was used for comparisons among the
LVSD, HFnEF type 1, HFnEF type 2, not HF, andmissing NT-proBNP groups.
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applied.Ofpatientswithanemiausingeither conservativeand
liberal criteria, 270 (43.2%) to 425 (68.0%) had a low serum
ironconcentrationorTSAT, comparedwith260 (14.7%) to624
(35.2%) of the patients without anemia (eFigures 1-4 in the
Supplement). The pattern was similar if confined only to pa-
tients who fulfilled the criteria for HF.
In a multivariable analysis (eTable 1 in the Supplement),
the characteristics that were strongly independently and
directlyassociatedwithhemoglobinconcentrationwereserum
iron (coefficient, 0.11; 95% CI, 0.10-0.12; P < .001), followed
by serum sodium (coefficient, 0.05; 95% CI, 0.04-0.07;
P < .001), heart rate (coefficient, 0.10; 95% CI, 0.07-0.13;
P < .001), and estimated glomerular filtration rate (coeffi-
cient, 0.01; 95%CI, 0.005-0.01;P < .001). A strong inverse as-
sociation between hemoglobin and logNT-proBNP was ob-
served, whereas women and those with confirmed HF had
lower hemoglobin concentrations. In further multivariable
analysis (eTable 2 in the Supplement), there were strong, in-
dependent inverse associations between serum iron andboth
hsCRP (coefficient,−0.23;95%CI,−0.25 to−0.21;P < .001) and
NT-proBNP (coefficient, −0.08; 95% CI, −0.11 to −0.05; P <
.001). Female sex (coefficient, −0.15; 95% CI, −0.20 to −0.10;
P < .001), diabetes (coefficient, −0.18; 95%CI, −0.24 to −0.17;
P < .001), peripheral edema (coefficient, −0.13; 95%CI, −0.20
Figure 1. Prevalence of Anemia by Severity and Cardiac Phenotype
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failure (HF)withpreserved left ventricular ejection fraction (HFnEF) type 1 is
definedas echocardiographic abnormalities that could account for symptomsand
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tricular systolic dysfunction (definedas a left ventricular ejection fraction <40%).
Figure 2. Prevalence of Hematinic Disorders by Severity of Anemia and Cardiac Phenotype
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to −0.07; P < .001), and use of mineralocorticoid antagonists
(coefficient, 0.12; 95% CI, 0.05 to 0.19; P < .001) were all
strongly related to lower serum iron concentration. In similar
multivariable models, ferritin was most strongly associated
with hsCRP (coefficient, 0.19; 95% CI, 0.15-0.22; t = 10.5;
P < .001), and vitamin B12 was most strongly associated with
lower bodymass index (calculated as weight in kilograms di-
videdbyheight inmeters squared) (coefficient, −0.01; 95%CI,
0.01 to −0.004; t = −4.55; P < .001) and higher serum ferritin
concentration (coefficient, 0.05; 95% CI, 0.03-0.07; t = 4.41;
P < .001).
In univariate analyses, lower concentrations of hemoglo-
bin and iron, lower TSAT, and higher concentrations of vita-
min B12 were strongly associated with all-cause and cardio-
vascular mortality (eTables 3 and 4 in the Supplement;
Figure 4A-F). The association between ferritin and prognosis
wasnonlinear,with the lowestandhighestquintileshaving the
worst outcome. In a multivariable model restricted to hema-
tinic variables and key clinical characteristics, the following
wereassociatedwithhigher all-causeandcardiovascularmor-
tality: lower hemoglobin and serum iron concentrations, the
highest quintile of ferritin, and higher serumvitamin B12 con-
centrations. If themodel was extended to include comorbidi-
ties, suchas findingsonphysical examination,otherbiochemi-
cal testing, and therapy (the last may be confounded by
indication and will change during follow-up), the indepen-
dent association between serum iron and all-cause mortality
was lost, but hemoglobin and vitamin B12 concentrations re-
mained weakly associated with outcome. If the analysis was
confinedtocardiovascularmortality, thenonlyserumironcon-
centration but neither hemoglobin nor vitaminB12 concentra-
tionwasassociatedwithoutcomeintheextendedmodel.Elimi-
nation of hemoglobin from the extendedmodel strengthened
the association of serum iron with outcomes and vice versa.
Figure 3. Association of Variables to the Probability of Anemia by Cardiac Phenotype Using Logistic RegressionModels
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All but 294 patients were followed up for at least 3 years.
By 3 years, mortality was similar in patients with LVSD (586
[32.7%]) and HFnEF type 1 (228 [32.3%]), somewhat lower in
HFnEF type2 (105 [22.6%]), andmarkedly lower among those
thought not tohaveHF (70 [8.3%];median age, 69years at re-
ferral) (eFigure 5 in the Supplement).Mortality increasedpro-
gressively as hemoglobin concentration decreased (eFigure 6
in the Supplement). A similar pattern was observed for se-
rum iron concentration (eFigure 7 in the Supplement). Among
patients with HF, most patients died suddenly or of worsen-
ingHF.Modeofdeathwassimilar in thosewithorwithoutane-
mia. Among patients who were considered not to have HF,
therewere fewcardiovascularandnoHFdeaths,but thosewho
had anemia or iron deficiency had a slightly higher cancer-
related mortality (eFigure 8 and eFigure 9 in the Supple-
ment).Fatalornonfatalgastrointestinalmalignant tumorswere
reported in32 (2.6%)of 1237patientswithanemiaand47 (1.5%)
of 3219patientswithout anemia,with similar rates across car-
diac phenotypes and according to iron deficiency.
Discussion
This analysis confirms that anemia is common in patients re-
ferred for investigation of suspected HF, especially if the di-
agnosis of HF is subsequently confirmed by objective evi-
dence of cardiac dysfunction. The prevalence of anemia is
similar regardless of the underlying HF phenotype and, even
if borderline, is often associated with iron deficiency. How-
ever, the prevalence of anemia and iron deficiency is highly
dependent on how these terms are defined; by some defini-
tions, most patients will have at least one or the other. Bone
marrow histologic analysis reveals a high prevalence of iron
depletion inpatientswithHF,20 reinforcing thebelief that iron
deficiency makes an important contribution to the develop-
ment of anemia in this setting.
An essential function of the circulation is to deliver oxy-
gen to tissues. The flow required will depend on local meta-
bolicactivityandtheamountofoxygenperunitofblood,which
is strongly related to the concentration of hemoglobin. Thus,
anemia, regardless of its cause,will increase cardiac demand,
which couldhave adeleterious effect on symptoms andprog-
nosis. Iron deficiencymay also be important in HF because it
is an essential component of myoglobin and the mitochon-
drial respiratory chain.21,22
ThecausesofanemiainpatientswithHFarecomplex.6Ane-
mia denotes a low hemoglobin concentration. Plasma volume
expansion or a decrease in red blood cell mass may cause the
hemoglobin concentration to decrease and the patient to be-
comeanemic20,23;plasmavolumeexpansionmaycontribute to
both anemia and an increase in natriuretic peptides andpartly
account forwhypatientswithHFhavea lowerhemoglobincon-
centration for a given level of iron deficiency. Worsening con-
gestion can cause anemia, which diuretics might correct, but
diuretics could also conceal reductions in red blood cell mass
bycausingdehydration.24Reductions inredbloodcellmassmay
Figure 4. Association Between Hematinic Variables and All-Cause or Cardiovascular Mortality at 2 Years by Cardiac Phenotype
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reflect reduced hematopoiesis due to iron deficiency or eryth-
ropoietin deficiency or resistance, associated with renal dys-
functionandactivationof inflammatorypathways.1,25Pharma-
cologic therapy for HF, including angiotensin-converting
enzyme inhibitors, carvedilol, and mineralocorticoid antago-
nists, is associated with a decrease in hemoglobin concentra-
tion, although the extent towhich this reflects plasma volume
expansionorareduction inredbloodcellmass isuncertain. Iron
deficiency may be related to impaired nutrition, reduced ab-
sorption attributable to increased production of hepcidin,26,27
a key regulator of iron homeostasis, or attributable to in-
creased losses fromthegastrointestinal orurinary tracts aggra-
vated by antithrombotic therapies.2 However, neither aspirin
nor warfarin was strongly linked to the presence of anemia in
the present study. Importantly,we identified a rather low inci-
denceof gastrointestinal cancers regardlessofwhether thepa-
tient had anemia. Our analysis shows that serum iron concen-
trationandTSAT,haveastrong inverseassociationwithhsCRP,
amarker of inflammation, althoughwhether this is a cause or
consequence of iron deficiencywe cannot tell. In contrast, se-
rumferritinwasdirectly related tohsCRP, suggesting thathigh
levelsmayreflect inflammationrather than ironrepletion in the
setting ofHF. Thus, there is a high risk that irondeficiencywill
bemissed ifbasedonserumferritinconcentration.Ontheother
hand, a threshold for serum ferritin concentration of less than
100 ng/mL identifiesmany patients with no other evidence of
irondeficiency.Accordingly, forpatientswithHF, its furtheruse
in clinical practice or for selecting patients for clinical trials
should be questioned.
The severity of anemia and iron deficiency were both
strongly related to all-cause and cardiovascular mortality on
univariate analyses. Patients with anemia were at increased
riskof suddenandHF-relateddeath. Eliminationof ironorhe-
moglobin from themultivariablemodel strengthened the as-
sociationof theotherwithoutcome.Therefore, it is likely that
both the severity of anemia and iron deficiency contribute to
an adverse outcome in patients with HF.
The lack of a robust blood test for iron deficiency creates
uncertainty about its role in the development of anemia.1
Anobservational study suchas this canhelp identifyhowsen-
sitive the prevalences of anemia and iron deficiency are to
changes indefinitionandtheir associationwithoutcome.How-
ever, demonstrating an associationbetween avariable and an
outcome does not prove causality. A series of trials demon-
strated that giving erythropoietin to patients with HF in-
creased hemoglobin concentrations and perhaps improved
well-being,5,7,8,28 but this did not translate into a benefit on
morbidity or mortality. Studies of intravenous iron have also
found an increase in hemoglobin concentration, symptoms,4
and exercise capacity,29,30 with hints that this might trans-
late into better long-term outcome.4,9
This was a single-center study serving a predominantly
white population but including a population ofmixed ethnic-
ity.Data shouldbeextrapolatedwith care to centers that serve
populationsdifferent fromours or if different criteria areused
todefineHF.However,weenrolledconsecutivepatients,which
may make this study more epidemiologically representative
thanmanymulticenter studies that enroll patients in a selec-
tive and nonconsecutive fashion.
Conclusions
In patients with heart failure, with or without a reduced left
ventricular ejection fraction, anemia and iron deficiency are
common and many patients have both, suggesting that iron
deficiency could be an important cause of anemia in this set-
ting. Serum concentrations of iron and transferrin saturation
aremore strongly associatedwith anemia thanare serumcon-
centrations of ferritin,whichmaybe greatly influencedby ac-
tivation of inflammatory pathways. Both anemia and ironde-
ficiencyareassociatedwithahigherall-causemortality,mostly
driven by cardiovascular deaths. The incidence of gastroin-
testinal malignant tumors is fairly low in patients with heart
failure andonly slightlyhigher inpatientswith anemiaor iron
deficiency. These data should help with the planning, execu-
tion, and interpretation of future interventional trials de-
signed to treat iron deficiency and/or anemia.
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